GenomeDx will use its Decipher Classifier and Genomics Resource Information Database to analyze samples, for tumor aggressiveness, and identify predictive signatures.
The company signed separate agreements with AstraZeneca, Merck, Merck KGaA, and Pfizer to create the panel, which is expected to help speed drug development.
The companies will co-develop kits, which Trovagene will distribute globally, to analyze ctDNA from blood or urine using next-generation sequencing platforms.
The partners will offer pharmaceutical firms a complete next-generation sequencing-based solution for the development and commercialization of companion diagnostic tests.
The two companies said they will integrate their technologies to create a sample management and interpretation and reporting system.
China-based Burning Rock will develop cancer diagnostics for Chinese patients based on the Agilent SureSelect target enrichment system.
The planned solution will enable secondary and tertiary analysis and visualization of single-cell sequence data.
The company said its organic revenue growth during the quarter was 4 percent, and that acquisitions increased revenue by 3 percent.
As part of a development and global distribution agreement, the companies will develop and launch a kit directed towards mitigating a growing HAI-related concern.
Thermo Fisher will become the exclusive distributor for a technology to be developed with Boston-based Cytonome.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.